Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 27, 2004, to report its first quarter 2004 financial results, as detailed in an attached press release dated April 26, 2004. This filing serves to inform investors about the company's financial performance and operational developments during the initial quarter of the year. The press release, incorporated by reference into the 8-K, provides the specific financial data and commentary that investors would typically review to assess Regeneron's business progress. The company is utilizing this Form 8-K filing to officially submit these results to the SEC, making them publicly available and part of the company's permanent record for regulatory purposes.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 27, 2004, reporting its first quarter 2004 financial results.
- 2The primary disclosure in this 8-K is a press release dated April 26, 2004, detailing the Q1 2004 results.
- 3This press release is incorporated by reference into the 8-K filing, making its contents part of the official SEC submission.
- 4The filing is made under Item 12 (Results of Operations and Financial Condition) and Item 7 (Financial Statements and Exhibits), specifically listing the press release as an exhibit.
- 5The information furnished under Item 12 and the press release are deemed 'filed' for purposes of the Securities Exchange Act of 1934.
- 6The Chief Financial Officer, Murray A. Goldberg, signed the report, indicating the official certification of the disclosed information.
- 7This 8-K serves as the formal mechanism for Regeneron to disseminate its quarterly financial performance to investors and the market.